Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Search by Keyword
Sort By
  • Public Health/Healthcare Delivery SIG: Methods for Conducting Healthare Delivery Research

    Product not yet rated Contains 5 Component(s) Recorded On: 10/22/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Given recent attention to healthcare reform efforts in the U.S., a greater emphasis is being placed on generating and synthesizing evidence to inform policies affecting the clinical practice of hepatology. In turn, this program will review and teach attendees about the most common research designs and analytic methods associated with the conduct of healthcare delivery research. Specifically, the topics of quality improvement methods, behavioral and health economics research, qualitative mixed-methods approaches, and health disparities research will be reviewed and discussed in depth through a series of interactive lectures and panel-based discussions. Examples based on the field of clinical hepatology and liver transplantation, including relevant peer-reviewed publications, will be highlighted.

    Michael Volk

    Elliot B. Tapper

    Dr. Elliot Tapper is Assistant Professor of Medicine at the University of Michigan Health System. Dr. Tapper’s research aims to improve the outcomes, quality of life and freedom from adverse events for patients with cirrhosis. His efforts focus on delineating quality indicators and developing interventions for the management and prevention of cirrhotic complications. His work on patient-centered, cost-effective diagnostic strategies for elevated liver enzymes have been published in journals including the American Journal of Gastroenterology, Journal of Hepatology, JAMA Internal Medicine, and the New England Journal of Medicine.

    David S. Goldberg

    Jessica L. Mellinger

    Benjamin Cook

  • Acute on Chronic Liver Failure SIG: Management of the Critically Ill Cirrhotic Patient: Improving Multidisciplinary Care and Avoiding…

    Contains 10 Component(s) Recorded On: 10/22/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Patients with acute-on-chronic liver failure frequently present to the ICU for care, and the mortality rate for cirrhotic patients requiring ICU approaches 50 percent.  Unique physiologic characteristics in the patient population warrant specialized, multidisciplinary, approaches to care.  The goal of this program is to further develop dialog between surgeons, hepatologists and intensive care unit teams to better deliver care to this complex patient population by focusing on the complex physiology of chronic liver failure.  In addition, we will devote special attention to areas of controversy in this patient group including initiation of renal replacement therapy, management of alcoholic hepatitis, defining futility and establishing appropriate goals of care.  

    Constantine J. Karvellas

    Dr. Constantine (Dean) Karvellas is an Associate Professor of Medicine (Critical Care Medicine and Gastroenterology/Hepatology) at the University of Alberta and an Adjunct Professor in the School of Public Health Sciences. He has been an attending intensivist in the E. Garner King General Systems Intensive Care Unit since 2009 and is involved with the Liver Transplant program as a Hepatologist. Dr. Karvellas is the only Canadian co-investigator in the NIH-funded United States Acute Liver Failure study group (US ALFSG). He is also a Vice Chair of the Society of Critical Care Medicine (SCCM) Liver management task force and serves as an Associate Editor for the Journal of Hepatology. Dr. Karvellas’ publications reflect his interests in acute liver failure (ALF), acute on chronic liver failure (ACLF), liver transplantation and extracorporeal liver support.

    Julia A. Wendon

    Mitra K. Nadim

    R. Todd Stravitz

    Hugo E. Vargas

    Hugo E. Vargas, MD, FAASLD is a Mayo Clinic Consultant in the Department of Gastroenterology and Hepatology and the Mayo Clinic Transplantation Center. He is the Medical Director for the Office of Clinical Research – Arizona, and a Professor of Medicine in the Mayo Clinic Alix School of Medicine. Dr. Vargas is the Chair of the Clinical Research Subcommittee, and the Vice Chair of the Arizona Research Operations Management Team.  

    Dr. Vargas has authored or coauthored more than 125 peer-reviewed articles. He is a Fellow of the AASLD, AGA, ACG, ASGE and ACP. He has been active in AASLD and has chaired the Annual Meeting Education Committee, Ethics Commiteee and co-chaired the AASLD/IDSA HCV group from 2016 to 2018. 

    Robert S. Rahimi

    Jennifer C. Lai

    Dr. Lai is a transplant hepatologist, on faculty at the University of California, San Francisco.  Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation.  Her primary research focuses on integrating core geriatric principles, such as frailty and physical function, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients.  She is the founder and principal investigator of the Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes.  For her work, she has been named a Beeson Scholar in Aging Research by the National Institute on Aging and a Top 40 Under 40 Leader by the San Francisco Business Times.

    Julie Heimbach

    Ayan Sen

    Puneeta Tandon

    Dr. Tandon is an Associate Professor of Medicine, Director of the Cirrhosis Care Clinic and Transplant Hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her Gastroenterology and Hepatology training at the University of Alberta with fellowships at Yale University and the Hospital Clinic in Barcelona. Her clinical practice and research are focused on cirrhosis. Research interests include acute on chronic liver failure and its related complications, sarcopenia, frailty, nutrition, exercise therapy and the early integration of palliative care principles in cirrhosis.

  • General Hepatology Update

    Contains 3 Component(s) Recorded On: 10/22/2017

    AASLD's General Hepatology Update presented at The Liver Meeting® 2017.

    This program will provide evidence-based and practical updates for three common and/or difficult-to-manage conditions: (1) how to select patients with the lowest likelihood of recidivism for liver transplant listing, (2) how to evaluate and manage acute and chronic venous outflow disorders; and (3) how to diagnose, evaluate and involve a multidisciplinary team in the management of patients with acute liver failure.

    Michael R. Lucey

    Dominique C. Vallas

    Robert J. Fontana

  • Transplant Surgery Workshop: Changing Donors, Recipients and Organ Use

    Product not yet rated Contains 8 Component(s) Recorded On: 10/21/2017

    AASLD's Transplant Surgery Workshop presented at The Liver Meeting® 2017.

    This program will look at current political issues related to organ allocation supported by data and an open debate, as well as changes in listing criteria. In addition, speakers will address best practices for the use of marginal livers and innovative treatment options to use such organs.

    Peter L. Abt

    Karen E. Doucette

    Dennis Irwin

    David S. Goldberg

    David J. Reich

    George E. Loss

    Karim Halazun

    Timothy L. Pruett

  • Liver Transplantation and Surgery Transplant SIG: Advances in Hepatocellular Carcinoma Therapy

    Product not yet rated Contains 9 Component(s) Recorded On: 10/21/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Attendees seeking an overview of the current diagnostic and therapeutic modalities available for patients with liver cancer will benefit from Advances in Hepatocellular Carcinoma Therapy. This session will cover a broad range of topics from epidemiology and future disease burden to the emerging role of genomics in the management of liver cancer. Attendees will also receive an overview of the role of surgical resection as well as the current indications for liver transplantation and post-transplant management and recurrence.

    Hashem B. El-Serag

    Julie Heimbach

    Jorge A. Marrero

    Laura M. Kulik

    Anjana A. Pillai

    Karim Halazun

    Vatche G. Agopian

    Mario Strazzabosco

    Neil Mehta

  • Career Development Workshop

    Product not yet rated Contains 7 Component(s) Recorded On: 10/20/2017

    AASLD's Career Development Workshop presented at The Liver Meeting® 2017.

    If you are considering a career in hepatology, this is the course for you. The Career Development Workshop will educate medical students or residents who are considering a career in hepatology about training opportunities as well as arm current GI and/ or hepatology fellows with knowledge to help them succeed in academic hepatology. Attendees will learn about clinical and basic science research, funding mechanisms, mentorship and important career crossroads. Community based, hybrid practices, and VA-based hepatology opportunities/practice models will be discussed, and an overview of the responsibilities and opportunities of an academic hepatologist and clinician educator will be highlighted. Lastly, through panel discussion, common questions regarding interview and contract negotiations will be reviewed.

    Michael D. Leise

    Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

    Oren K. Fix

    Oren K. Fix, MD, MSc, FAASLD is Medical Director of the Liver Transplant Program at Swedish Medical Center in Seattle. He earned his medical degree at SUNY Buffalo School of Medicine and a masters degree in Epidemiology from Boston University School of Public Health. He completed his Internal Medicine residency and Gastroenterology fellowship at Boston University and Transplant Hepatology fellowship at University of California San Francisco (UCSF). Dr. Fix was a site principal investigator in the NIH-funded Acute Liver Failure Study Group for 8 years at University of Washington and UCSF. He has published over 45 peer-reviewed manuscripts and book chapters, many on the topic of acute liver failure.

    William Sanchez

    Harmeet Malhi

    Archita P. Desai

    Meena B. Bansal

    Meena B. Bansal, MD, FAASLD is currently Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai, Deputy Chief Medical Officer for Mount Sinai Health Partners, and Vice President, Population Health for Quality and Efficiency. Dr. Bansal attended Harvard University and then Cornell Medical School. She did her internship and residency at Cornell Medical School and then completed Gastroenterology Fellowship at the University of Pennsylvania in 2001.

    Her current research interests focus on the impact of HIV on hepatic inflammation and fibrosis. She became the Director of Translational Research in the Division of Liver Diseases in 2013 and has been principal investigator for numerous clinical trials ranging from HCV to NASH. In 2013, she became the Medical Director of all Hospital-based Clinics at Mount Sinai. In this latter role she developed an interest in population health and the challenges of the evolving health care landscape. Over the past 5 years, her focus has also been on building a population health infrastructure that will allow a large academic health system to be successful in value-based care.

    Mark W. Russo

  • Clinical Research Workshop

    Product not yet rated Contains 3 Component(s) Recorded On: 10/20/2017

    AASLD's Clinical Research Workshop presented at The Liver Meeting® 2017.

    With the rising epidemic of NASH and NASH-related end stage liver disease, there is a pressing need to better define the pathogenesis of NASH, identify meaningful biomarkers and effective treatments. This workshop aims to bring together investigators from bench to bedside to identify the best methods of collaboration at the translational level, determine how to define meaningful endpoints, and work in teams across disciplines, institutions and with pharma to address this epidemic.

    Anna Mae Diehl

    Manal F. Abdelmalek

    Manal F. Abdelmalek, MD, MPH is tenured Professor of Medicine in the Division of Gastroenterology and Hepatology and Director of the NAFLD Clinical Research Program at Duke University. She received training in Internal Medicine, Gastroenterology and Hepatology at the Mayo Clinic, Scottsdale AZ and Rochester, MN and obtained a MPH degree with emphasis in epidemiology, public health and clinical investigation at the University of Florida, Gainesville, Florida.  Since first reporting on nonalcoholic fatty liver disease (NAFLD) as a cause of cryptogenic cirrhosis over 20 years ago, her clinical and research area of interest have been in the field of NAFLD, its associated risk factors for disease acquisition and progression and novel approaches to treatment. She has expertise in the design and conduct of clinical trials in NAFLD/ NASH including investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD.  She collaborates extensively to translate new compounds to first-in-man clinical studies and the translation of clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression.  Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease.  She is a standing member of NASH Clinical Research Network (NASH CRN).  She has over 150 publications authored publications in the field of liver disease, the majority of which are in the area of NAFLD. 

    Jag Chhatwal

  • Liver Cell Biology in Hepatic Diseases SIG: DAMPs and New Receptor Signaling in Liver Disease

    Product not yet rated Contains 4 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Gain a solid background on the mechanisms that activate and potentiate hepatic injury, inflammation and fibrosis through an in-depth presentation of the different yet related basic molecular mechanisms that underlie various types of hepatic damage.

    Melanie J. Scott

    Xiaoxia Li

    Nissiam Hay

    Yingzi Yang

  • Hepatotoxicity SIG: Drig-Induced Liver Injury Due to Chemotherapeutic Agents

    Contains 6 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    A look at both traditional and new chemotherapeutic agents associated with liver injury will help attendees gain a working knowledge of agents that can cause liver injury, how the injury presents, and how to make the diagnosis. This program also offers new insight on the challenges for chemotherapeutic drug development, approval and post-marketing surveillance in the U.S.

    Jay H. Hoofnagle

    Robert J. Fontana

    K. Rajender Reddy

    Laurie D. DeLeve

    Arie Regev

    Lorraine Pelosof

  • Hepatitis B SIG: Getting to HBV Cure: The Path Forward

    Contains 12 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    There is a critical need for curative therapy for hepatitis b (HBV). This program will systematically review the various approaches to achieving this goal. Attendees will gain a greater appreciation for the challenges in developing new HBV therapies and discover where new therapies will fit into the future treatment landscape for this disease.

    Jordan J. Feld

    Su H. Wang

    Robert G. Gish

    Dr. Robert G. Gish is a Clinical Professor of Medicine at the University of Nevada in Las Vegas and is a senior consultant at St Joseph’s Medical Center in Phoenix as well as Professor Consultant, Stanford University. In 2013, he founded the consulting company Robert G. Gish Consultants, LLC to provide consultative support to Pharma, nonprofits and hepatology centers and liver transplant programs that wish to start or grow their programs through pathways of quality and optimal patient care that is integrated with research and education. Dr. Gish began his medical training in 1974 when he was enrolled in the pharmacy school at the University of Kansas and then transferred to the University of Kansas Medical School in 1977 and finished his Doctor of Medicine degree in 1980. Dr. Gish went on to complete a three year internal medicine residency at the University of California, San Diego and a four-year gastroenterology and hepatology fellowship at the University of California, Los Angeles. Dr. Gish has had and continues to have an active research program in viral hepatitis, liver transplant, bio-artificial liver, and public policy especially related to liver cancer, liver transplantation, and viral hepatitis.

    Jorg Petersen

    Stephen Locarnini

    Adam J. Gehring

    Scott D. Holmberg

    Mindie H. Nguyen

    Mindie H. Nguyen, MD, MAS, AGAF, FAASLD is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology, School of Medicine, Stanford University in Palo Alto, California, USA. Her main fields of scientific and clinical interest are the epidemiology and management of chronic viral hepatitis, non-alcoholic fatty liver disease and liver cancer, with over 100 peer- reviewed scientific journal articles. She has served as a member of the Steering Committee for the Hepatobiliary Neoplasia Special Interest Group, HBV Special Interest Group, Education Committee and the Hepatology Associate Committee for the AASLD and as research mentor for over 100 trainees and faculty.

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.



    Ju-Tao Guo

    Barbara Rehermann